- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06643780
RANK-ligandinhibering för att bekämpa sarkopeni med underliggande osteoporos
RANK-ligand-hämning för att bekämpa sarkopeni med underliggande osteoporos: en randomiserad, dubbelblind, dubbeldummy, aktivt kontrollerad försök
The objective of this study was to conduct a randomized, double-blind, double-dummy active controlled trial to determine the efficacy of denosumab in treating sarcopenia with underlying osteoporosis.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Aims:
- To assess whether receptor activator of nuclear factor-kB ligand (RANKL)-inhibition can treat sarcopenia in osteosarcopenic patients, in terms of appendicular skeletal muscle mass (ASM), handgrip strength, and physical performance.
- To assess whether RANKL-inhibition improves quality of life, and decreases falls, fractures, hospital admissions and mortality in osteosarcopenic patients.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 4
Kontakter och platser
Studiekontakt
- Namn: Ronald Man Yeung Wong
- Telefonnummer: 852 3505 1654
- E-post: ronald.wong@cuhk.edu.hk
Studieorter
-
-
-
Hong Kong, Kina
- Rekrytering
- The Chinese University of Hong Kong
-
Kontakt:
- Ronald Man Yeung Wong
- Telefonnummer: 852 3505 1654
- E-post: ronald.wong@cuhk.edu.hk
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Elderly males or females aged 65 years or older
- diagnosed with osteosarcopenia (sarcopenia diagnosis based on AWGS 2019 guidelines - low appendicular skeletal muscle mass (ASM) by Dual-energy X-ray absorptiometry (DXA) (M:<7.0kg/m2, F:<5.4kg/m2) AND low handgrip strength (M:<28kg, F:<18kg) OR low physical performance (6-metre walk: <1.0m/s or 5-time chair stand test ≥ 12 s); osteoporosis diagnosed based on World Health Organization (WHO) criteria with DXA scan T-score ≤ -2.5)
- Willing and able to comply with study protocol including follow-up evaluations.
Exclusion Criteria:
- history of recent fracture i.e., within 3 months
- history of prior anti-osteoporotic drug
- disease or medication affecting bone or muscle metabolism
- Chairbound or bedbound
- Unable to agree for consent
- contraindication to drug i.e., Denosumab or Zoledronic Acid
- Underlying malignancy or disease known to cause cachexia
- severe renal impairment e.g., Creatinine Clearance (CrCl) < 35ml/min
- moderate to severe liver failure (Child-Pugh Class B or C).
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Denosumab group
60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly |
60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly |
|
Placebo-jämförare: Zolendronic acid group
5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months |
5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
6-metre walk
Tidsram: From enrollment to the end of treatment at 52 weeks
|
The time taken to walk 6 metres without deceleration. Average result of 2 trials is recorded. Slow speed is defined as &lt;1.0m/s. |
From enrollment to the end of treatment at 52 weeks
|
|
5-time chair stand test
Tidsram: From enrollment to the end of treatment at 8 weeks
|
The time to rise from a chair 5 times is recorded. The cut-off for is taken at &gt;=12 seconds. |
From enrollment to the end of treatment at 8 weeks
|
|
Appendicular skeletal muscle mass (ASM)
Tidsram: From enrollment to the end of treatment at 52 weeks
|
Determined with Dual-energy X-ray absorptiometry (Horizon®, DXA system, Hologic, USA). Total ASM by DXA is evaluated by segmented measurement of muscle mass at four limbs by operator-defined cutlines at specific anatomical landmarks. ASM is adjusted to square of height to calculate ASMI (kg/m2). Low ASMI by DXA is &lt; 7 kg/m2 for men and 5.4 kg/m2 for women. |
From enrollment to the end of treatment at 52 weeks
|
|
Handgrip strength
Tidsram: From enrollment to the end of treatment at 52 weeks
|
Assessed by spring-type hand dynamometer (JAMAR Hand Dynamometer 5030JO). Cut-off for men is &lt; 28kg, and female is &lt;18kg. Maximum reading of 3 trials using dominant hand in a maximum-effort isometric contraction |
From enrollment to the end of treatment at 52 weeks
|
|
Quadriceps muscle strength
Tidsram: From enrollment to the end of treatment at 52 weeks
|
Measured on affected limb with isometric dynamometer (Baseline, Genova, Italy). Subject will sit on a chair with both feet above ground, while raising the affected leg 45° forwards. The dynamometer is placed above the ankle and the subject will push the leg forward with maximum force. Measurements will be repeated 3 times and maximum value will be used for evaluation |
From enrollment to the end of treatment at 52 weeks
|
|
Balancing ability
Tidsram: From enrollment to the end of treatment at 52 weeks
|
The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes directional control (%). |
From enrollment to the end of treatment at 52 weeks
|
|
Balancing ability
Tidsram: From enrollment to the end of treatment at 52 weeks
|
The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes movement velocity (degrees/s) |
From enrollment to the end of treatment at 52 weeks
|
|
Balancing ability
Tidsram: From enrollment to the end of treatment at 52 weeks
|
The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes endpoint excursion (%) |
From enrollment to the end of treatment at 52 weeks
|
|
Balancing ability
Tidsram: From enrollment to the end of treatment at 52 weeks
|
The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes maximum excursion (%) |
From enrollment to the end of treatment at 52 weeks
|
|
Balancing ability
Tidsram: From enrollment to the end of treatment at 52 weeks
|
The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes reaction time(s) |
From enrollment to the end of treatment at 52 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Falls
Tidsram: From enrollment to the end of treatment at 52 weeks
|
To assess the occurrence of falls, patients are required to self-report via a fall calendar, which will be returned at 1-year |
From enrollment to the end of treatment at 52 weeks
|
|
Fracture
Tidsram: From enrollment to the end of treatment at 52 weeks
|
Assess occurrence of a fracture within a year of study period. |
From enrollment to the end of treatment at 52 weeks
|
|
Quality of life Short Form-36 (SF-36)
Tidsram: From enrollment to the end of treatment at 52 weeks
|
The highest score is 900, and the lowest score is 0. Highest score indicates a better quality of life. |
From enrollment to the end of treatment at 52 weeks
|
|
Physical activity scale for elderly (PASE)
Tidsram: From enrollment to the end of treatment at 52 weeks
|
It assesses the types of activities typically chosen by older adults, ranging from 0 to 793, with higher scores indicating greater physical activity |
From enrollment to the end of treatment at 52 weeks
|
|
Food frequency questionnaire
Tidsram: From enrollment to the end of treatment at 52 weeks
|
Daily and weekly intake of 280 food items will be performed using a validated food frequency questionnaire developed in a local population survey. Mean nutrient quantitation and energy intake per day will be calculated referring to food composition tables derived from the Chinese Medical Sciences Institute and Centre for Food Safety in Hong Kong. |
From enrollment to the end of treatment at 52 weeks
|
|
Hospital admissions
Tidsram: From enrollment to the end of treatment at 52 weeks
|
Number and cause of emergency hospital admission within 1 year of study period are documented. |
From enrollment to the end of treatment at 52 weeks
|
|
Mortality
Tidsram: From enrollment to the end of treatment at 52 weeks
|
Mortality within 1-year of study period is documented. |
From enrollment to the end of treatment at 52 weeks
|
Samarbetspartners och utredare
Samarbetspartners
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2022.555
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .